Entering text into the input field will update the search result below

Phase 3 trials for Merck-NewLink Ebola vaccine start this week in Guinea

Mar. 05, 2015 10:47 AM ETMerck & Co., Inc. (MRK) StockGSK, MRK, LUMOBy: Douglas W. House, SA News Editor
  • Phase 3 trials to assess the safety and efficacy of the experimental Ebola vaccine co-developed by Merck (MRK +0.2%) and NewLink Genetics (NLNK +0.8%) will commence in two days in Guinea according to a statement by the World Health Organization (WHO). The trials will be conducted in the Basse Guinee region which dealt with the most Ebola cases.
  • A "ring vaccination" strategy will be employed whereby everyone who has been in contact with a newly diagnosed Ebola patient will be vaccinated, an approach used to eradicate smallpox in the 1970s.
  • Trials of two vaccine candidates, Merck/NewLink and GlaxoSmithKline (GSK +0.1%), in Liberia appear to be working. No new cases have been reported for 13 days.
  • Trials for Glaxo's offering will begin in Guinea when supplies are available.

Recommended For You

More Trending News

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.